CVS · Q3 2025 Earnings

Cautious

CVS Health

Reported October 29, 2025

30-second summary

Revenue grew 7.8% to $102.9B and adjusted EPS came in at $1.60, with management raising FY adjusted EPS guidance by $0.25 to $6.55–$6.65 — the second consecutive quarterly raise. Underneath, GAAP EPS was -$3.13 on a $5.7B Oak Street goodwill impairment, dragging full-year GAAP guidance from $3.84–$3.94 to a loss of $(0.34)–$(0.24). The PCW turnaround accelerated (11.7% revenue growth, 28.9% pharmacy share, FY segment guide raised from -5% to +3%), but Health Services FY guidance was cut by $240M attributed to Caremark drug-mix headwinds (Oak Street outlook largely unchanged), and Oak Street's terminal value was repriced — the operating story is improving while the asset base is being quietly written down.

Headline numbers

EPS

Q3 FY2025

$1.60

Revenue

Q3 FY2025

$102.87B

+7.8% YoY

Operating margin

Q3 FY2025

-3.1%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$102.87B	+7.8%	$98.92B	+4.0%
EPS	$1.60	—	$1.81	-11.6%
Operating margin	-3.1%	—	2.4%	-551bps

Guidance

CVS raised full-year Adjusted EPS guidance by $0.25 at midpoint while reversing GAAP earnings to a loss range, reflecting a material one-time charge that does not affect operational performance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY2025	$6.30 to $6.40	$6.55 to $6.65	+$0.25 at midpoint (low +$0.25, high +$0.25)	Raised
GAAP diluted EPS	FY2025	$3.84 to $3.94	$(0.34) to $(0.24)	Reversed from positive to negative; $4.18-$4.28 decline at range midpoints	Lowered

Reaffirmed unchanged this quarter: Cash flow from operations ($7.5 billion to $8.0 billion)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Health Care Benefits	$35.993B	+9.1%
Health Services	$49.266B	+11.6%
Pharmacy & Consumer Wellness	$36.214B	+11.7%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Medical Benefit Ratio (MBR)	92.8%
Medical Membership	26.7 million
Days Claims Payable	42.5 days
Pharmacy Claims Processed (30-day equiv.)	475.6 million
Prescriptions Filled (30-day equiv.)	461.4 million
Adjusted Operating Income	$3.459 billion
Caremark Contract Wins	$6.0 billion
Medicare Advantage Star Ratings (4+ stars)	81% of members

Management tone

Q2 anchor: Aetna recovery → Q3 anchor: stabilization and rationalization.

The press release language moved from Q2's "significant and durable recovery at Aetna" and "strong retention at CVS Caremark" to Q3's narrower framing of "stabilized operations" and a focus on "businesses and markets where we can succeed." That is a meaningful step down in ambition tone — from recovery to stabilization, from growth to selectivity. The phrase "businesses and markets where we can succeed" is corporate code for footprint trimming.

The Q3 disclosure pattern reinforces this: the $5.7B Oak Street impairment, the decision to reduce new primary care clinic openings in 2026 and thereafter, and the closure of underperforming clinics together signal that management has decided value-based care is a smaller business than the 2023 acquisition thesis assumed. Q2's tone treated Oak Street as a temporary medical-cost-trend headwind; Q3's tone treats it as a structurally smaller opportunity that needed terminal-value repricing. That is not a small shift.

On Caremark, the tone moved from Q2's confidence in retention to Q3's defensive clarification that headwinds are drug-mix-driven, not TrueCost-driven. Management disaggregated the issue as a market-basket guarantee structure problem — mix and utilization differed from forecast on a subset of contracts — and explicitly framed mitigations as having "not materialized as quickly or have the impact we'd initially anticipated." The willingness to publicly attribute the headwind to contract structure rather than fold it into a generic "industry pressure" line is a credibility-positive disclosure choice, but the need to repeatedly clarify suggests the market had begun to read TrueCost as the source of margin compression.

PCW is the one segment where the tone strengthened. The 800bps swing in segment guide from -5% to +3%, combined with quantified share gains (400bps in immunizations, 28.9% pharmacy share), supports management's framing of a structural turnaround rather than a one-quarter beat.

Q&A highlights

Lisa Gill · JP Morgan

Asked about PBM headwinds from transparency/true cost transition, anticipated future headwinds during contracting, and future PBM economics for both CVS and plan sponsors using rebates to offset premiums.

Management explained that $240M headwind is not from true cost model transition but from market basket-based guarantee structures where drug mix and utilization differed from forecast. Emphasized Caremark's 30-year track record of innovation and adaptation, strong $6B new client wins, and high 90s retention despite industry challenges. Discussed true cost as the pricing model of the future with 25M+ members in point-of-sale rebate programs.

$240 million near-term headwind to health services segment$6 billion in new client wins in latest selling seasonHigh 90s retention rate achieved25+ million members in point-of-sale rebate programs

Justin Lake · Wolf Research

Asked about PCW (pharmacy and consumer wellness) Q3 outperformance, drivers for assumed 3% Q4 growth, vaccine volume headwinds, and impact of Rite Aid 600-store acquisition on Q4 and 2026.

Management highlighted strong execution and leadership in PCW business, 11.7% top-line script growth, pharmacy market share at 28.9%, and Rite Aid integration as contributor. Noted ability to offset lower vaccine demand with 400bps market share gains. Emphasized improved front-store performance with positive comps, 2.6% customer base growth, and 2.7% trip growth. Segment guidance raised to 3% growth (vs. initial -5% guidance).

11.7% script growth in Q3Pharmacy market share at 28.9%400 basis points of immunization market share gains2.6% customer base growth

Eric Percher · Nephron Research

Asked whether Caremark pressure was from true cost adoption versus drug mix changes, and whether changes were from GLP-1 formulary decisions or biosimilar private labels impacting rebate guarantees.

Management clarified that headwinds are NOT from true cost model. Instead, three primary drivers: (1) slower GLP-1 adoption with expected compounding volumes returning but not materializing; (2) autoimmune category product drivers; (3) HIV category drivers. Stated they're actively working with clients to adjust guarantees. Emphasized ongoing client wins and market leadership despite short-term pressure.

Headwinds NOT from TrueCost modelSlower GLP-1 adoption in back half of yearSpecific pressure from autoimmune and HIV category productsWorking with clients to adjust guarantees

Stephen Baxter · Wells Fargo

Asked about $500M of core upside in prior quarters that wasn't flowing through guidance, equivalent upside in Q3 after excluding out-of-period items, and clarification on whether mid-teens 2026 EPS growth is after adjusting the 45 cents of out-of-period items.

Management provided specific reconciliation: Year-to-date out-of-period items totaled approximately 45 cents ($900M in H1, plus $150M provider settlements in Q3). Mid-teens 2026 growth should be calculated by taking $6.60 midpoint of 2025 guidance, subtracting 45 cents, then applying mid-teens growth rate. Explained conservative approach to guidance reflects prudent outlook on medical cost trends and macro factors.

45 cents of out-of-period items embedded in 2025 results2026 EPS guidance baseline: $6.60 less $0.45 = $6.15Mid-teens growth rate applies to adjusted baseline$900 million in out-of-period items in first half 2025

Andrew Muck · Barclays

Asked about pre-tax operating losses at Oak Street Health, whether problematic external membership drove benefit design changes for 2026, and what contracting changes are being made including risk shifts to Medicare Advantage partners.

Management declined to share specific pre-tax loss figures but indicated focus on clinic growth slowdown and terminal value impairment. Emphasized Oak Street performance was in-line with expectations and value-based care remains strategically critical. Three focus areas: (1) fair and equitable payer contracts ensuring sustainability; (2) continued clinical model and technology enhancements; (3) slowing clinic growth and growing membership within existing clinics. Noted V28 impact in line with expectations.

Oak Street Q3 performance in line with expectations$5.7 billion goodwill impairment taken on healthcare delivery segmentClinic growth rate being deliberately slowedFocus on growing membership within existing clinics

Answers to last quarter's watch list

Group MA repricing cadence on the 2026 renewal cohort — The press release flagged 81% of MA members in 4-star or higher plans for 2026, a positive setup for bid economics, but management did not disclose specific Group MA bid actions or further PDR adjustments this quarter. Brian Newman flagged "repricing opportunities in our group business" as a 2026 tailwind.

Continue monitoring

MBR trajectory below 90% — MBR came in at 92.8%, down 240bps YoY but sequentially higher. Management disclosed ~100bps of Q3 noise (provider liabilities + individual exchange risk adjustment), implying ~91.8% underlying. FY MBR now projected at ~91% at the low end of the HCB guide range.

Continue monitoring

PCW reimbursement run-rate holding — PCW posted 11.7% revenue growth, with segment FY guide raised from -5% to +3% (an 800bps cumulative swing from initial guide). The reimbursement improvement held and broadened into share gains.

Resolved positively

Oak Street operating economics — Management took a $5.7B goodwill impairment, decided to reduce new clinic openings in 2026 and thereafter, and announced closure of underperforming clinics. The mitigation actions are now articulated; pre-tax loss quantification was not provided.

Continue monitoring

Caremark 2026 selling-season wins — Disclosed $6B in new client wins with high-90s retention. This validates the Q2 "strong start" framing on the win side, though the $240M Health Services FY guide cut on Caremark drug-mix headwinds partially offsets the narrative.

Resolved positively

What to watch into next quarter

Oak Street pre-tax operating losses — management did not quantify in Q3; watch for explicit disclosure at the December 9th Investor Day, plus any sizing of the "slowed clinic growth" decision in unit terms.

MBR Q4 print and full-year exit rate — FY guide now implies ~91% at the low end of the HCB range; watch whether Q4 prints in line or breaks higher as Part D seasonality completes, which would signal a deeper HCB normalization than the adjusted-EPS raise implies.

2026 EPS baseline confirmation — management gave a $6.60 less $0.45 = ~$6.15 baseline plus mid-teens growth in Q&A; watch whether the formal 2026 guide at the December 9th Investor Day confirms this math or quietly re-anchors lower as Oak Street and Caremark dynamics play out.

Caremark contract repricing duration — management framed the recontracting as a multi-year process; watch for any extension or quantified offsets in Q4 and at Investor Day.

Further GAAP-vs-adjusted gap expansion — Q3 had a $5.7B impairment plus an $83M Health Care Delivery clinic closure charge. Watch the Q4 print for any additional non-cash charges that would suggest balance-sheet repricing is not yet complete.

Sources

CVS Health Q3 2025 press release (SEC 8-K, Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/64803/000006480325000036/cvs_ex99x1q3-25.htm
CVS Health Q3 2025 earnings call Q&A excerpts (transcript partial).
CVS Health Q2 2025 brief (Tapebrief, prior-quarter reference).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.